Replacement of meningioma animal models with a meningioma ex vivo/organoid model to test pharmacological advances in meningioma treatment
Intracranial connective tissue tumors (meningiomas) derive from the meninges of the brain and are predominantly benign (80-90%). They are one of the most frequent intracranial tumors - most prevalent in women (female:male ratio 2:1). Tumors in near proximity to vital structures such as the brainstem, large blood vessels or in surgically less accessible areas are difficult to remove completely. Surgical treatment remains primary treatment – alternatively radiotherapy. None of these without significant risk of damaging healthy brain and other vital structures. Meningiomas, which are not completely removed have a 20-44 % chance of tumor recurrence. Medical treatment options have been tested since the 1980’s, however with limited success and as of now, no effective medical treatment is available.
Meningiomas often express progesterone receptors on the surface of their cells. Another type of tumor which resembles meningiomas in many regards is the benign muscle tumor (leiomyoma), which grows in the uterus. This tumor is often dependent of progesterone receptors for tumor development. Leiomyomas can be treated with hormone-suppressing therapy, for instance the selective progesterone receptor modulator (SPRM).
Sign up for our newsletter - don't miss information about our annual symposium etc.